brexpiprazole

FDA Drug Profile — Rexulti

brexpiprazole is listed in the FDA National Drug Code directory with 18 NDC codes, marketed under brand name including Rexulti. Available dosage forms: tablet, powder.

Drug details

Generic Name
brexpiprazole
Brand Names
Rexulti
Application Number
NDA205422
Sponsor
Otsuka America Pharmaceutical, Inc.
NDC Codes
18
Dosage Forms
TABLET, POWDER
Routes
ORAL
Active Ingredients
BREXPIPRAZOLE

Indications and Usage

1 INDICATIONS AND USAGE REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] . REXULTI is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults and pediatric patients ages 13 years and older ( 1 , 14.2 ) Treatment of agitation associated with dementia due to Alzheimer's disease ( 1 , 14.3 ) Limitations of Use : REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.